A Study of CLN-978, a Subcutaneously Administered CD19-directed T Cell Engager, in Subjects With Sjogren's Disease
NCT07041099 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 36
Last updated 2026-03-23
Summary
A phase 1b, open-label study of CLN-978 administered subcutaneously in patients with active, moderate to severe Sjogren's Disease.
Conditions
- Sjögren
- Sjogren Disease
- Sjogren's Syndrome
Interventions
- DRUG
-
CLN-978
Specified dose on specified days
Sponsors & Collaborators
-
Cullinan Therapeutics Inc.
lead INDUSTRY
Study Design
- Allocation
- NON_RANDOMIZED
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- SEQUENTIAL
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2025-10-01
- Primary Completion
- 2028-03-15
- Completion
- 2029-03-15
- FDA Drug
- Yes
Countries
- United States
- France
- Germany
- Italy
Study Locations
More Related Trials
-
Pharmacokinetics Study of Ianalumab in Chinese Participants With Autoimmune Diseases
NCT06411639 ·Status: WITHDRAWN ·Phase: PHASE1
-
A Study of RSLV-132 in Subjects With Primary Sjogren's Syndrome
NCT03247686 ·Status: COMPLETED ·Phase: PHASE2
-
A Trial to Evaluate the Efficacy and Safety of Sibeprenlimab Administered Subcutaneously in Participants With Sjögren's
NCT06928142 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
A Phase 1 Study of SYNCAR-001 + STK-009 Without Conditioning Chemotherapy (Lymphodepletion) in Subjects With Severe, Refractory Systemic Autoimmune Rheumatic Disease
NCT06544330 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1
-
A Study to Evaluate the Efficacy and Safety of Dazodalibep in Participants With Sjögren's Syndrome (SS) With Moderate-to-severe Systemic Disease Activity
NCT06104124 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
A Study to Evaluate a Single-Dose Subcutaneous Axatilimab Compared With Intravenous Axatilimab in Healthy Participants
NCT06713590 ·Status: COMPLETED ·Phase: PHASE1
-
Study to Assess Safety and Effectiveness of Branebrutinib Treatment in Participants With Active Systemic Lupus Erythematosus or Primary Sjögren's Syndrome, or Branebrutinib Treatment Followed by Open-label Abatacept Treatment in Study Participants With Active Rheumatoid Arthritis
NCT04186871 ·Status: COMPLETED ·Phase: PHASE2
-
Determining the Responses and Impact of Rituximab-instigated Cell Depletion on T Cells in People With SLE
NCT01702038 ·Status: WITHDRAWN ·Phase: PHASE2
-
A Study to Evaluate the Efficacy and Safety of Telitacicept in Subjects With Active Primary Sjogren's Syndrome
NCT05673993 ·Status: COMPLETED ·Phase: PHASE3
-
Preliminary Clinical Study of UTAA09 Injection in the Treatment of Relapsed/Refractory Autoimmune Diseases
NCT06417398 ·Status: NOT_YET_RECRUITING ·Phase: EARLY_PHASE1
-
A Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple Subcutaneous Injections of SHR-2173 in Patients With Systemic Lupus Erythematosus
NCT06955598 ·Status: COMPLETED ·Phase: PHASE1
-
A Study to Assess Adverse Events, How the Drug Moves Through the Body and Effectiveness of Intravenous Infusions of ABBV-319 in Adult Participants With Systemic Lupus Erythematosus (SLE) and Sjogren's Disease (SjD)
NCT06977724 ·Status: RECRUITING ·Phase: PHASE1
-
Tolerance and Efficacy of Rituximab in Sjogren's Disease
NCT00740948 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
A Clinical Study of YTS109 Cells for the Treatment of R/R Autoimmune Diseases
NCT07123519 ·Status: RECRUITING ·Phase: PHASE1
-
Treating Systemic Lupus Erythematosus (SLE) Patients With CTLA4-IgG4m (RG2077)
NCT00094380 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
A Phase 1b Study of Budoprutug in Systemic Lupus Erythematosus (SLE)
NCT07011043 ·Status: RECRUITING ·Phase: PHASE1
-
On Open-Label Study in Participants With Systemic Lupus Erythematosus
NCT01488708 ·Status: TERMINATED ·Phase: PHASE3
-
A Study to Assess CLBR001+SWI019 in Subjects With Autoimmune Diseases
NCT06913608 ·Status: WITHDRAWN ·Phase: PHASE1
-
Interferon Signature in Anti-CTLA-4 and Anti-PD-1/PD-L1-Treated Cancer Patients Compared With Systemic Autoimmune Disease Patients
NCT07249060 ·Status: RECRUITING
-
A Phase II Study to Evaluate the Efficacy and Safety of SHR-1314 in Lupus Nephritis
NCT04924296 ·Status: UNKNOWN ·Phase: PHASE2
-
Efficacy and Safety of Mycophenolate Mofetil in subjectswithSjogren's Syndrome
NCT02691949 ·Status: UNKNOWN ·Phase: PHASE2
-
A Safety and Efficacy Study of Dazodalibep in Participants With Sjögren's Syndrome (SS) With Moderate-to-Severe Symptom State
NCT06245408 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
Double-Blinded, Randomized, Placebo-Controlled Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Biochemical Activity of Intravenous Cpn10 Administration in Subjects With Mild to Moderate SLE.
NCT01838694 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
A Research Study to Evaluate the Effects of a New Oral Medicine Called Cenerimod in Adults With Systemic Lupus Erythematosus
NCT05648500 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
A Long-term Extension Study of Dazodalibep in Participants With Sjögren's Syndrome (SS)
NCT06747949 ·Status: RECRUITING ·Phase: PHASE3